Top > Search of International Patents > Method for detection of disease having insulin-resistant conditions

Method for detection of disease having insulin-resistant conditions

Foreign code F110003466
File No. A261-07WO
Posted date Jun 27, 2011
Country United States of America
Application number 30199707
Gazette No. 20100273192
Gazette No. 8465930
Date of filing May 29, 2007
Gazette Date Oct 28, 2010
Gazette Date Jun 18, 2013
International application number JP2007061246
International publication number WO2007139224
Date of international filing May 29, 2007
Date of international publication Dec 6, 2007
Priority data
  • P2006-149328 (May 30, 2006) JP
  • 2007WO-JP61246 (May 29, 2007) WO
Title Method for detection of disease having insulin-resistant conditions
Abstract (US8465930)
Disclosed is a simple method for detecting a pathological condition of an insulin-resistant disease, particularly type-2 diabetes.
The method comprises quantifying the ganglioside GM3 in a blood sample separated from a living body.
More specifically, the method comprises the following steps (a) to (c): (a) separating a plasma or serum from the blood collected from a human; (b) quantifying the ganglioside GM3 in the plasma or serum; and (c) comparing the quantified ganglioside GM3 level to the mean ganglioside GM3 level determined in blood samples from healthy volunteers.
Scope of claims [claim1]
1. A method for detection of a disease selected from the group consisting of type 2 diabetes and type 2 diabetes combined with hyperlipidemia, wherein said type 2 diabetes group having a Body Mass Index level greater than 30, which comprises: separating plasma or serum from human blood collected;
quantifying ganglioside GM3 in the plasma or serum separated; and,
comparing the GM3 level quantified to a mean ganglioside GM3 level in blood samples derived from healthy volunteers, thereby detecting the disease.
[claim2]
2. The method for detection according to claim 1, wherein said quantification of ganglioside GM3 is performed by high performance liquid chromatography (HPLC), high performance thin layer chromatography (HPTLC), high performance liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS) or enzyme linked immunosorbent assay (ELISA) using an anti-GM3 antibody.
[claim3]
3. The method according to claim 1, wherein said disease is type 2 diabetes.
[claim4]
4. A method for predicting a risk of developing a disease selected from the group consisting of type 2 diabetes and type 2 diabetes combined with hyperlipidemia, wherein said type 2 diabetes group having a Body Mass Index level greater than 30, which comprises: separating plasma or serum from human blood collected;
quantifying ganglioside GM3 in the plasma or serum separated;
comparing the GM3 level quantified to a normal ganglioside GM3 level in blood samples from healthy volunteers; and
monitoring changes in the ganglioside GM3 level, thereby predicting the risk.
[claim5]
5. The method according to claim 4, wherein said quantification of ganglioside GM3 is performed by high performance liquid chromatography (HPLC), high performance thin layer chromatography (HPTLC), high performance liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS) or enzyme linked immunosorbent assay (ELISA) using an anti-GM3 antibody.
[claim6]
6. The method according to claim 4, wherein a blood sample is regularly collected from the human and changes in the ganglioside GM3 level in the blood sample collected are monitored.
[claim7]
7. The method according to claim 4, wherein said disease is type 2 diabetes.
[claim8]
8. The method of claim 1, wherein the disease is type 2 diabetes combined with hyperlipidemia.
[claim9]
9. The method of claim 1, wherein the disease is a diabetic group having a Body Mass Index level greater than 30.
[claim10]
10. The method of claim 4, wherein the disease is type 2 diabetes combined with hyperlipidemia.
[claim11]
11. The method of claim 4, wherein the disease is a diabetic group having a Body Mass Index level greater than 30.
  • Inventor, and Inventor/Applicant
  • INOKUCHI JINICHI
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
IPC(International Patent Classification)
Reference ( R and D project ) CREST Clarification of the Biological Functions of Sugar Chains and the Use of this Knowledge in Applied Technologies AREA
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close